CREST与ACT-1支架置入与动脉内膜切除试验中无症状颈动脉狭窄的年龄效应
汇总CREST与ACT-1两项随机试验中2544例年龄<80岁、≥70%无症状颈动脉狭窄患者,按<65、65-69、70-74、75-79岁分层比较颈动脉支架置入(CAS)与颈动脉内膜切除(CEA)。主要终点各年龄层无治疗差异;75-79岁组CAS较CEA的围手术期卒中或死亡或4年内同侧卒中风险升高(10% vs 2%;HR 4.41;95%CI 1.31-14.83)。
要点
- 主要终点(围手术期卒中、心肌梗死或死亡,或其后同侧卒中)在各年龄层CAS与CEA间无差异(P>.05)。
- 75-79岁患者随机至CAS者卒中或死亡风险约为CEA者的4倍(10% vs 2%;HR 4.41;95%CI 1.31-14.83)。
- 随机至CAS者中75-79岁较<65岁主要终点风险升高(11% vs 4%;HR 2.90;95%CI 1.52-5.53);CEA各组年龄层无差异(P>.1)。
核心结论
- 汇总CREST与ACT-1的2544例无症状患者显示,仅75-79岁年龄组CAS较CEA的卒中或死亡风险更高,随机至CAS的75-79岁患者风险增加,而随机至CEA者未见年龄相关风险增加。
研究设计与样本
- 对CREST与ACT-1两项比较CAS与CEA的随机试验进行汇总分析,纳入2544例年龄<80岁、≥70%无症状颈动脉狭窄患者(CREST 1091例;ACT-1 1453例),2000至2013年入组,年龄分<65、65-69、70-74、75-79岁四层。
主要发现
- 主要终点各年龄层CAS与CEA间无治疗差异(P>.05)。
- 次要终点卒中或死亡:75-79岁随机至CAS者风险约为CEA者4倍(10% vs 2%;HR 4.41;95%CI 1.31-14.83)。
- <65、65-69、70-74岁三层CAS与CEA间未检出治疗差异(P>.05)。
- 随机至CAS者中75-79岁较<65岁主要终点风险更高(11% vs 4%;HR 2.90;95%CI 1.52-5.53),其他层间无显著差异(P>.05)。
- 随机至CEA者各年龄层间无差异(P>.1)。
关键数值与推荐
- 75-79岁随机至CAS者卒中或死亡10% vs 随机至CEA者2%(HR 4.41;95%CI 1.31-14.83)。
- 随机至CAS者75-79岁主要终点11% vs <65岁4%(HR 2.90;95%CI 1.52-5.53)。
- 主要终点各年龄层CAS与CEA比较P>.05;<65、65-69、70-74岁三层卒中或死亡CAS与CEA比较P>.05;随机至CEA者年龄层间比较P>.1。
临床怎么用
- 作者认为,鉴于2013年以来CAS的进展,75岁以上无症状患者的临床管理必须个体化以优化结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed if age was an effect modifier in a pooled analysis of two randomized trials comparing carotid artery stenting (CAS) and carotid endarterectomy (CEA) in asymptomatic patients, CREST and ACT-1. METHODS: We analyzed data from 2544 patients aged <80 yearas with ≥70% asymptomatic carotid stenosis randomized to CAS or CEA (nCREST = 1091; nACT-1 = 1453) who were recruited between 2000 and 2013. Age was considered in four strata (<65, 65-69, 70-74, and 75-79 years). The primary outcome was any stroke, myocardial infarction, or death during the peri-procedural period, or ipsilateral stroke afterwards. The secondary outcome of any stroke or death during the peri-procedural period or ipsilateral stroke within 4 years was also analyzed. RESULTS: For the primary outcome, there were no CAS vs CEA treatment differences within any age stratum (P > .05). For the secondary outcome of stroke or death, those randomized to CAS age 75 to 79 yearas were at approximately four times greater risk compared with those randomized to CEA (10% vs 2%; hazard ratio, 4.41; 95% confidence interval, 1.31-14.83). No treatment differences between CAS and CEA were detected for the three younger age strata, <65, 65 to 69, and 70 to 74 years (P > .05). For patients randomized to CAS, the risk of the primary endpoint for those aged 75 to 79 years was higher than the risk for those age <65 years (11% vs 4%; hazard ratio, 2.90; 95% confidence interval, 1.52-5.53), without significant differences between other strata (P > .05). For those randomized to CEA, there were no differences between age strata (P > .1). CONCLUSIONS: This pooled analysis of 2544 asymptomatic patients in CREST and ACT-1 shows a higher stroke or death risk for CAS compared with CEA in only the oldest age group, 75 to 79 years. For patients randomized to CAS, there was an increased risk for patients aged 75 to 79 years. No increased risk by age was found for patients randomized to CEA. Hence, the clinical management of asymptomatic patients above age 75 years must be individualized to optimize outcomes in the context of advances in CAS since 2013.
引用
- Voeks JH, Hanlon B, Brott TG, et al. Age effect in asymptomatic carotid stenosis in the CREST and ACT-1 stenting vs endarterectomy trials. J Vasc Surg. 2024. PMID: 39694153. doi:10.1016/j.jvs.2024.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。